AMSTERDAM, THE NETHERLANDS – Norgine B.V., a leading European specialty pharmaceutical company, has announced a significant breakthrough for pediatric oncology patients in Switzerland. Swissmedic, the Swiss Agency for Therapeutic Products, has officially granted marketing authorization for PEDMARQSI® (sodium thiosulfate solution for infusion). This groundbreaking approval specifically targets the prevention of cisplatin-induced ototoxicity, a severe and often irreversible form of hearing loss, in patients aged 1 month to less than 18 years who are undergoing treatment for localized, non-metastatic solid tumors. This authorization represents a crucial advancement, as PEDMARQSI® stands as the first and only pharmacological treatment explicitly developed and approved to address this devastating side effect in young cancer patients within Switzerland.
Addressing a Critical Unmet Medical Need in Pediatric Oncology
Cisplatin, a potent platinum-based chemotherapy agent, remains an indispensable cornerstone in the treatment protocols for various pediatric solid tumors, including hepatoblastoma, osteosarcoma, germ cell tumors, and medulloblastoma. Its efficacy in eradicating cancer cells has undeniably saved countless young lives and improved prognosis significantly over decades. However, the therapeutic benefits of cisplatin come with a formidable and well-documented side effect profile, with ototoxicity – damage to the inner ear leading to hearing loss – being among the most debilitating and prevalent. This hearing impairment can manifest rapidly, often after the very first dose of chemotherapy, and has a tendency to progress over the course of treatment and even post-treatment, becoming irreversible for many children.
The impact of cisplatin-induced hearing loss on a developing child extends far beyond the inability to hear. It profoundly affects critical developmental milestones, including speech and language acquisition, which are foundational for cognitive and social growth. Children experiencing hearing loss often face significant educational challenges, requiring specialized support and potentially impacting their academic performance and future career prospects. Socially and psychologically, the condition can lead to isolation, reduced self-esteem, and difficulties in forming peer relationships, ultimately diminishing their overall quality of life. For parents and caregivers, managing a child’s cancer diagnosis is already an immense burden, and the added stress of anticipating or managing severe, permanent hearing loss adds another layer of complexity and heartache. Until now, medical professionals in Switzerland have largely been limited to reactive measures, such as audiological monitoring and supportive interventions like hearing aids or cochlear implants, none of which prevent the initial damage. The approval of PEDMARQSI® thus fills a gaping void in pediatric supportive care, offering a proactive, preventative solution.
PEDMARQSI®: A New Era of Preventative Care
PEDMARQSI® is a novel formulation of anhydrous sodium thiosulfate, meticulously developed and manufactured to protect the delicate hair cells of the inner ear from the cytotoxic effects of cisplatin. While the exact mechanism of action is complex, sodium thiosulfate is believed to act as a chelating agent, binding to and inactivating cisplatin metabolites that can cause ototoxicity, thereby preventing their harmful interaction with inner ear cells. It may also function as an antioxidant, neutralizing reactive oxygen species generated by cisplatin that contribute to cellular damage. This targeted approach allows the chemotherapy to continue its life-saving work against cancer cells while simultaneously safeguarding the child’s hearing.
The significance of this approval was underscored by Rüdiger Merkel, General Manager, DACH, at Norgine, who stated, "The Swissmedic approval of PEDMARQSI® represents an important milestone for children, families and healthcare professionals in Switzerland, where no approved pharmacological option has previously been available to help prevent this complication of cisplatin treatment. Hearing loss can have a lifelong impact on young patients, and this approval supports access to a treatment developed specifically to address this unmet medical need." His statement highlights not only the medical achievement but also the profound human impact this treatment is expected to have on the lives of young cancer survivors.
Robust Clinical Evidence Underpins Swissmedic’s Decision
The marketing authorization granted by Swissmedic is founded on a robust body of clinical evidence derived from two pivotal, open-label, randomized Phase 3 trials: the SIOPEL 6 study and the Clinical Oncology Group (COG) ACCL0431 study. These trials rigorously evaluated the safety and efficacy of sodium thiosulfate when administered alongside cisplatin chemotherapy in the target pediatric population.
The SIOPEL 6 trial, which specifically focused on children with hepatoblastoma, demonstrated compelling results. Patients randomized to receive sodium thiosulfate in conjunction with cisplatin experienced a significantly lower incidence of ototoxicity compared to those receiving cisplatin alone. Similarly, the COG ACCL0431 study, which enrolled a broader spectrum of pediatric solid tumor patients, corroborated these findings. Across both studies, the collective data revealed an approximate 50% reduction in the occurrence of cisplatin-induced ototoxicity in the sodium thiosulfate treatment arm. Crucially, this significant reduction in hearing loss was achieved without compromising the anti-tumor efficacy of cisplatin chemotherapy, ensuring that the primary goal of cancer treatment remained unhindered. This dual benefit – preventing a debilitating side effect while maintaining therapeutic potency – is a critical factor for any adjunctive cancer therapy.
The safety profile observed in these trials was also favorable. The most commonly reported adverse events associated with sodium thiosulfate administration were nausea and vomiting, which are often overlapping with side effects of chemotherapy itself. More severe (Grade 3–4) adverse events reported included infection, anemia, and neutropenia. These events are frequently observed in pediatric cancer patients undergoing intensive chemotherapy regimens and were generally manageable, suggesting that sodium thiosulfate does not introduce a prohibitive additional toxicity burden. The consistent findings across two independent, large-scale Phase 3 trials provided Swissmedic with the necessary confidence to approve PEDMARQSI® as a safe and effective preventative measure.
A Broader Regulatory Journey and Global Impact
The Swissmedic approval is part of a broader regulatory trajectory for PEDMARQSI® across international markets. Prior to this, the European Medicines Agency (EMA) granted paediatric use marketing authorisation (PUMA) for PEDMARQSI® in May 2023. This PUMA designation is specifically designed to encourage the development and availability of medicines for children, recognizing the unique challenges and ethical considerations involved in pediatric drug development. Following the EMA’s decision, PEDMARQSI® also received national marketing authorization in the United Kingdom. These successive approvals underscore the consistent and compelling evidence base supporting the drug’s efficacy and safety, paving the way for its wider adoption and ensuring that more children battling cancer can benefit from this preventative treatment.
The coordinated efforts of regulatory bodies like Swissmedic and the EMA, alongside pharmaceutical companies such as Norgine, are vital in addressing the specific needs of vulnerable patient populations like children. Historically, pediatric drug development has lagged behind adult therapeutics due to smaller patient populations, ethical complexities of conducting trials in children, and perceived economic disincentives. The PUMA mechanism and similar initiatives in other regions are designed to overcome these hurdles, fostering innovation that directly benefits pediatric patients. The successful journey of PEDMARQSI® through these rigorous regulatory pathways serves as an encouraging precedent for future pediatric drug development.
Implications for Pediatric Oncology Practice in Switzerland
The introduction of PEDMARQSI® in Switzerland is poised to significantly alter the standard of care for pediatric patients receiving cisplatin. Oncologists will now have a clinically proven tool to mitigate one of the most feared long-term complications of this life-saving chemotherapy. This will allow for more aggressive and potentially more effective cisplatin dosing in some cases, without the previous level of concern for debilitating ototoxicity. Furthermore, it is expected to lead to substantial improvements in the long-term quality of life for cancer survivors, reducing the need for costly and often lifelong audiological interventions and specialized educational support.
From a healthcare system perspective, while there is an upfront cost associated with the drug, the prevention of severe hearing loss can lead to long-term economic benefits by reducing the expenses related to hearing aids, cochlear implants, speech therapy, and special education services that would otherwise be incurred over decades. More importantly, the societal benefit of enabling children to live fuller, more integrated lives, pursuing their education and careers without the significant impediment of hearing loss, is immeasurable. Patient advocacy groups and parents of children undergoing cancer treatment are expected to welcome this development wholeheartedly, recognizing the profound impact it will have on families navigating the challenging journey of pediatric cancer.
Norgine’s Commitment to Addressing Unmet Needs
Norgine B.V., with its approximately 1,500 employees and annual sales of around $650 million, positions itself as a mid-sized EU-based pharmaceutical company driven by innovation. Its mission is to deliver medicines that genuinely change lives, focusing on both common conditions and rare, severe diseases such as childhood cancer. The successful development and regulatory approval of PEDMARQSI® exemplify Norgine’s core philosophy: that every scientific breakthrough, no matter how niche the patient population, deserves to reach those in need.
The company leverages its innovative development, commercialization, and manufacturing capabilities, alongside strategic partnerships, to navigate the often-complex pathways of drug development and market access. Norgine’s extensive history and deep regional expertise in Europe, Australia, and New Zealand enable it to accelerate and expand the reach of life-changing medicines. The approval of PEDMARQSI® reinforces Norgine’s strategic focus on specialty products that address significant unmet medical needs, particularly in areas where existing treatment options are limited or non-existent. Guided by the trust placed in them by healthcare professionals and patients, Norgine remains steadfast in its commitment to delivering innovations that transform lives, one patient at a time. The successful journey of PEDMARQSI® from clinical trials to market authorization in multiple regions stands as a testament to this commitment and promises a brighter future for young cancer patients.
The authorization of PEDMARQSI® in Switzerland marks a pivotal moment in pediatric cancer care, offering a beacon of hope for thousands of children and their families. It not only provides a tangible solution to a long-standing and devastating side effect of life-saving treatment but also underscores the relentless pursuit of medical innovation aimed at improving the quality of life for the youngest and most vulnerable patients. As PEDMARQSI® becomes integrated into clinical practice, it is expected to set a new standard for supportive care in pediatric oncology, ensuring that children who overcome cancer can do so with their hearing intact, ready to embrace a future full of possibilities.